9999999997-17-000384.txt : 20170127 9999999997-17-000384.hdr.sgml : 20170127 20170127102240 ACCESSION NUMBER: 9999999997-17-000384 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170127 DATE AS OF CHANGE: 20170127 20170127 20170127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDO HEALTH SOLUTIONS INC. CENTRAL INDEX KEY: 0001100962 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134022871 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1933 Act SEC FILE NUMBER: 333-39040 FILM NUMBER: 17552047 BUSINESS ADDRESS: STREET 1: 1400 ATWATER DRIVE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 4842160000 MAIL ADDRESS: STREET 1: 1400 ATWATER DRIVE CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: ENDO PHARMACEUTICALS HOLDINGS INC DATE OF NAME CHANGE: 19991214 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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end